Day One Biopharmaceuticals (NASDAQ:DAWN) Insider Sells $67,442.40 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Lauren Merendino sold 5,814 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $67,442.40. Following the sale, the insider owned 60,157 shares of the company’s stock, valued at $697,821.20. The trade was a 8.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Day One Biopharmaceuticals Stock Down 2.7%

Shares of DAWN traded down $0.32 during trading hours on Wednesday, reaching $11.56. The company’s stock had a trading volume of 1,478,926 shares, compared to its average volume of 2,543,632. The company has a 50 day moving average of $10.28 and a two-hundred day moving average of $8.55. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -7.61 and a beta of -1.26. Day One Biopharmaceuticals, Inc. has a 1-year low of $5.64 and a 1-year high of $13.20.

Analyst Upgrades and Downgrades

DAWN has been the subject of a number of research reports. Piper Sandler lifted their target price on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. lifted their price objective on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Zacks Research upgraded shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 26th. Finally, TD Cowen began coverage on shares of Day One Biopharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating and a $34.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $25.71.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. AIGH Capital Management LLC acquired a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter valued at $10,719,000. AlphaQuest LLC boosted its position in Day One Biopharmaceuticals by 1,065.6% in the third quarter. AlphaQuest LLC now owns 185,006 shares of the company’s stock valued at $1,304,000 after buying an additional 169,134 shares in the last quarter. Schroder Investment Management Group bought a new stake in Day One Biopharmaceuticals during the second quarter worth about $1,171,000. Geode Capital Management LLC increased its holdings in shares of Day One Biopharmaceuticals by 11.2% during the second quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company’s stock worth $11,132,000 after buying an additional 171,964 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd raised its stake in shares of Day One Biopharmaceuticals by 71.7% in the second quarter. Dynamic Technology Lab Private Ltd now owns 83,223 shares of the company’s stock valued at $541,000 after acquiring an additional 34,766 shares during the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.